An alternative to sterile testing in the isolator! Designed to separate the container and dish with just a pinch.
The "MicroFunnel ST Filter Funnel" can be used as an alternative to high-cost closed-system aseptic testing conducted with isolators and similar equipment. The 0.45 μm, 47 mm GN-6 Metricel membrane and low-adsorption Supor membrane are suitable for aseptic testing applications in the pharmaceutical industry. The design allows for easy separation of the container and plate with just a pinch, making membrane removal simple. It complies with the aseptic testing requirements of the United States Pharmacopeia, Japanese Pharmacopoeia, and European Pharmacopoeia. 【Features】 ■ Can be used as an alternative to high-cost closed-system aseptic testing conducted with isolators and similar equipment ■ Suitable for aseptic testing applications in the pharmaceutical industry ■ Supor membrane is ideal for antibiotic testing ■ Easy separation of the container and plate with just a pinch, making membrane removal simple ■ Complies with the aseptic testing requirements of the United States Pharmacopeia, Japanese Pharmacopoeia, and European Pharmacopoeia *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Lineup】 ■0.45 μm Supor membrane, colorless, 100 mL ■0.45 μm Supor membrane, colorless, 300 mL ■0.45 μm GN-6 Metricel membrane, 100 mL ■0.45 μm GN-6 Metricel membrane, 300 mL *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Application】 ■Microbial contamination testing of aqueous solutions using this product and the MF method ■Quality control analysis of aqueous solutions used in pharmaceutical production ■Quality control testing before the shipment of the final product *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.